Author details

Full Name

Marc Debouverie

Affiliation

ORCID

Career Start Year

1988

Papers

137

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36564207	Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.		2023
36426377	Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.	Lancet Regional Health - Europe, The	2023
37827849	Comparison of Two Methods for Estimating MS-Related Mortality: The Excess Mortality vs. the Cause-Specific Frameworks.		2023
37650895	Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.		2023
36841644	A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study.		2023
36496270	Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod.		2023
34893353	Evaluation of the quality of the care pathway for patients with multiple sclerosis in France: Results of an original study of a cohort of 700 patients.	Revue Neurologique	2022
36083790	Prognostic impact of epileptic seizures in multiple sclerosis varies according to time of occurrence and etiology.	European Journal of Neurology	2022
35637426	Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.	BMC Medical Research Methodology	2022
35977837	Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.	Neurology	2022
35046460	Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France.	Scientific Reports	2022
34505304	Comparative effectiveness of dimethyl fumarate in multiple sclerosis.	British Journal of Clinical Pharmacology	2022
35217934	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.		2022
34895909	Cognitive impairment in glycogen storage disease type III with severe heart failure: A case report.	Revue Neurologique	2022
35183366	Developing tools to evaluate quality of care management for patients living with multiple sclerosis: An original French initiative.	Revue Neurologique	2022
34536228	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.	CNS Drugs	2021
34017332	Mass Cytometry Identifies Expansion of T-bet B Cells and CD206 Monocytes in Early Multiple Sclerosis.	Frontiers in Immunology	2021
34116480	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.	Multiple Sclerosis and Related Disorders	2021
33791847	Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.	Journal of Neurology	2021
33838072	Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort.	European Journal of Neurology	2021
33830650	Comparison of Simoa and Ella to assess serum neurofilament-light chain in multiple sclerosis.	Annals of Clinical and Translational Neurology	2021
33933001	Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data.	BMC Med Res Methodol	2021
34193589	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.	Neurology	2021
33124504	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.	Multiple Sclerosis Journal	2021
33326668	Assessing the experience of the quality of care of patients living with multiple sclerosis and their caregivers: The MusiCare questionnaire.	European Journal of Neurology	2021
33269975	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.	Multiple Sclerosis Journal	2021
33423618	Determinants of therapeutic lag in multiple sclerosis.	Multiple Sclerosis Journal	2021
33403937	Cumulative effects of therapies on disability in relapsing multiple sclerosis.	Multiple Sclerosis Journal	2021
30541380	Observatoire FranÃ§ais de la SclÃ©rose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.	Multiple Sclerosis Journal	2020
32369661	Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis.	Journal of Clinical Apheresis	2020
32475261	Memory improvement in multiple sclerosis after an extensive cognitive rehabilitation program in groups with a multicenter double-blind randomized trial.	Clinical Rehabilitation	2020
32600454	The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial.	Trials	2020
32617659	Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.	Journal of Neurology	2020
30707357	High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.	Journal of Neurology	2019
29722639	Efficacy of rituximab in refractory RRMS.	Multiple Sclerosis Journal	2019
31081475	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.	Multiple Sclerosis Journal	2019
30948262	Dronabinol use in France between 2004 and 2017.	Revue Neurologique	2019
31300547	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.	Neurology	2019
28298039	Interactions between glioma and pregnancy: insight from a 52-case multicenter series.	J Neurosurg	2018
29996003	Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.	European Journal of Neurology	2018
29673575	Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?	Revue Neurologique	2018
29695592	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.	Neurology	2018
29370274	Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy.	PLoS ONE	2018
29584762	Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.	PLoS ONE	2018
29808469	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.	CNS Drugs	2018
28099355	Hereditary spastic paraplegia due to a novel mutation of the REEP1 gene: Case report and literature review.	Medicine (United States)	2017
28793296	Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.	Neuroepidemiology	2017
28516332	Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.	Journal of Neurology	2017
29141801	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?	Multiple Sclerosis and Related Disorders	2017
29209268	Implementation and Evaluation of an Economic Model for Telestroke: Experience from , France.	Frontiers in Neurology	2017